Navigation Links
Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress
Date:3/23/2017

SAN DIEGO and VANCOUVER, British Columbia, March 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that data from its successful Phase 2a study of topsalysin, which evaluated the drug as a focal treatment for localized prostate cancer, will be presented as a poster on March 26, 2017 at the 32nd Annual European Association of Urology in London, UK. The poster has been selected by conference organizers as one of the best posters at the congress.

Abstract No. 758: "Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study"
Presenting Author:  Dr. Yaalini Shanmugabavan, Division of Surgery and Interventional Sciences, University College London, London, UK
Poster Session:  Poster Session 57 – Prostate cancer: Is the future focal?
Time:  March 26, 2017 from 3:45 pm – 5:15 pm GMT

The abstract related to the poster can be accessed through the European Association of Urology Congress website at http://eau17.uroweb.org/.

About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.  More than 400 patients have received treatment with topsalysin, which continues to appear to be safe and well tolerated. For more information, please visit www.sophirisbio.com.

Company Contact:
Peter Slover
Chief Financial Officer
(858) 777-1760

Corporate Communications and Media Contact:
Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/topsalysin-data-from-successful-phase-2a-localized-prostate-cancer-study-to-be-presented-at-the-32nd-european-association-of-urology-congress-300428644.html


'/>"/>
SOURCE Sophiris Bio Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
3. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
4. Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
5. Following the Successful Launch in the United States, the New Simbionix U/S Mentor to be Introduced for the First Time in Europe
6. Marken Successfully Launches Quality Agreement Workshop Series
7. Varian Software Successfully Connected with Siemens Linear Accelerators
8. Ensil Canada Announces First Successful Test and Validation of Vastusys Line of Products in Ontario Laboratories
9. Educating Key Stakeholder to Support a Successful Diabetes Product Launch
10. Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
11. New Blood Clot Removal System Successfully Restores Blood Flow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... 2019 , ... A new study published today in JAMA ... identity from transgender to cisgender is associated with a range of adverse mental ... Fenway Institute, Massachusetts General Hospital (Harvard Medical School), and McLean Hospital (Harvard Medical ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... a period of rediscovery and attraction from big pharma, nutraceutical manufacturers, food companies, ... and North American use rates are expected to rise as access to hemp-derived ...
(Date:9/11/2019)... (PRWEB) , ... September 11, 2019 , ... ... today announced that elder care innovator HomeThrive has selected LifePod’s voice-first service for ... as unpaid caregivers to adults over the age of 50, demand has steadily ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... September 11, 2019 , ... Autopsies don’t lie. They report the ... body. , Methamphetamine permanently harms the heart. It increases risks of heart attack ... understanding of how the damage occurs. , An August 1, 2019 article ...
(Date:9/11/2019)... ... September 11, 2019 , ... Executives at health systems ... change in the healthcare industry over the past several years has been intense. For ... The future of healthcare in America will depend largely on how these executives respond. ...
(Date:9/11/2019)... ... September 10, 2019 , ... Four Shriners for ... physicians have been recognized among the best doctors in the San Gabriel Valley ... Robert H. Cho, M.D. – Chief of Staff, scoliosis, spinal deformity ...
(Date:9/11/2019)... ... ... Dimensional Insight®, a data management, analytics and performance management company, ... Boston. To be held on Saturday, Sept. 28 on the Boston Common, the event ... St. Jude Children’s Research Hospital®. , “At Dimensional Insight, we believe that ...
(Date:9/9/2019)... ... September 09, 2019 , ... ... recently attended the American Association of Dental Office Management (AADOM) Annual Conference. This ... the Year (PAOY) award. This is Sharon’s third nomination in a row. The ...
Breaking Medicine News(10 mins):